Aclaris Therapeutics Provides Corporate Update
– ATI-1777 Phase 2a Trial Results Published in JID Innovations –
– ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 –
– Aclaris Announces Reduction in Workforce –
Related news for (ACRS)
- MoBot’s Stock Market Highlights – 07/29/25 06:00 PM
- MoBot alert highlights: NASDAQ: TYGO, NASDAQ: MBRX, NASDAQ: ACRS, NASDAQ: GIBO, NASDAQ: BSLK (07/29/25 05:00 PM)
- Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
- MoBot’s Stock Market Highlights – 07/29/25 04:00 PM
- 24/7 Market News Snapshot 29 July, 2025 – Aclaris Therapeutics, Inc. (NASDAQ:ACRS)